OncoMatch/Clinical Trials/NCT06792825
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Is NCT06792825 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tafasitamab and Rituximab for follicular lymphoma.
Treatment: Tafasitamab · Rituximab · Lenalidomide — The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evaluated separately. This study is presented to the patient and consent is signed prior to the initiation of treatment for their primary malignancy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
Histologically confirmed CD20+ follicular lymphoma
Disease stage
Required: Stage I, II, 3A
Histologically confirmed CD20+ follicular lymphoma stage 1, 2 or 3a
Prior therapy
Cannot have received: lenalidomide (lenalidomide)
Prior history of lenalidomide use
Cannot have received: systemic therapy
No prior systemic therapy for lymphoma
Lab requirements
Blood counts
Adequate organ function within 14 days (28 days for pulmonary or cardiac) of study registration
Kidney function
Adequate organ function within 14 days (28 days for pulmonary or cardiac) of study registration
Liver function
Adequate organ function within 14 days (28 days for pulmonary or cardiac) of study registration
Cardiac function
Adequate organ function within 28 days of study registration
Adequate organ function within 14 days (28 days for pulmonary or cardiac) of study registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Masonic Cancer Center · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify